Ocumension Therapeutics (1477.HK)
1477.HK Stock Price Chart
Explore Ocumension Therapeutics interactive price chart. Choose custom timeframes to analyze 1477.HK price movements and trends.
1477.HK Company Profile
Discover essential business fundamentals and corporate details for Ocumension Therapeutics (1477.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jul 2020
Employees
489.00
Website
https://www.ocumension.comCEO
Ye Liu
Description
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
1477.HK Financial Timeline
Browse a chronological timeline of Ocumension Therapeutics corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 31 Mar 2025
EPS came in at -$0.17 surpassing the estimated -$0.19 by +9.39%, while revenue for the quarter reached $265.61M , missing expectations by -0.59%.
Earnings released on 12 Aug 2024
EPS came in at -$0.25 falling short of the estimated -$0.23 by -9.27%, while revenue for the quarter reached $180.01M , missing expectations by -1.18%.
Earnings released on 22 Mar 2024
EPS came in at -$0.29 surpassing the estimated -$0.31 by +5.57%, while revenue for the quarter reached $157.91M , missing expectations by -2.73%.
Earnings released on 25 Aug 2023
EPS came in at -$0.35 falling short of the estimated -$0.35 by -0.84%, while revenue for the quarter reached $112.14M , missing expectations by -15.14%.
Earnings released on 31 Mar 2023
EPS came in at -$0.37 surpassing the estimated -$0.38 by +2.60%, while revenue for the quarter reached $118.93M , beating expectations by +3.72%.
Earnings released on 27 Aug 2022
EPS came in at -$0.36 falling short of the estimated -$0.27 by -33.49%, while revenue for the quarter reached $63.84M , beating expectations by +51.60%.
Earnings released on 26 Mar 2022
EPS came in at -$0.38 surpassing the estimated -$0.47 by +19.18%, while revenue for the quarter reached $43.27M , missing expectations by -23.67%.
Earnings released on 21 Aug 2021
EPS came in at -$0.14 surpassing the estimated -$0.35 by +59.76%, while revenue for the quarter reached $24.98M , missing expectations by -37.70%.
Earnings released on 20 Mar 2021
EPS came in at -$1.15 falling short of the estimated -$0.75 by -53.72%, while revenue for the quarter reached $13.23M , missing expectations by -68.29%.
1477.HK Stock Performance
Access detailed 1477.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.